Bank of Montreal vs GeneDx Holdings Corp — how do they compare? Bank of Montreal trades at $180.98 (market cap $125.53B), while GeneDx Holdings Corp trades at $62.44 (market cap $1.85B). The key difference: Bank of Montreal is far larger — about 67.9× GeneDx Holdings Corp's market cap, and Bank of Montreal pays a 2.74% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| BMO | WGS | |
|---|---|---|
Market Cap | $125.53B | $1.85B |
Sector | Financials | Technology |
52-Week High | $180.86 | $167.51 |
52-Week Low | $110.44 | $34.51 |
Dividend Yield | 2.74% | — |
Enterprise Value | — | $1.85B |
Signals from Pluang's Aura AI — not financial advice
BMO trades at $178.69, down 0.15% today, with a bullish technical signal supported by moving averages and key resistance at $180. The company reported strong Q1 2026 earnings of $2.68 per share, beating estimates, and maintains a solid net income margin of 25.92%. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings.
Outlook remains positive driven by consistent earnings beats and expansion in metals & mining banking. Risks include valuation above historical norms with a P/E of 19.48 and exposure to interest rate sensitivity. The stock offers a compelling dividend yield but faces macroeconomic headwinds that could pressure future performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →